よむ、つかう、まなぶ。
03 資料１－１ 帯状疱疹ワクチンファクトシート (71 ページ)
出典
| 公開元URL | https://www.mhlw.go.jp/stf/newpage_40826.html |
| 出典情報 | 厚生科学審議会 予防接種・ワクチン分科会 予防接種基本方針部会 ワクチン評価に関する小委員会（第26回 6／20）《厚生労働省》 |
ページ画像
ダウンロードした画像を利用する際は「出典情報」を明記してください。
低解像度画像をダウンロード
プレーンテキスト
資料テキストはコンピュータによる自動処理で生成されており、完全に資料と一致しない場合があります。
テキストをコピーしてご利用いただく際は資料と付け合わせてご確認ください。
75.
Asano Y, Shiraki K, Takahashi M, Nagai H, Ozaki T, Yazaki T. Soluble skin test antigen of varicella-zoster virus
prepared from the fluid of infected cultures. J Infect Dis 1981; 143(5): 684-92.
76.
Wood MJ, Kay R, Dworkin RH, Soong SJ, Whitley RJ. Oral acyclovir therapy accelerates pain resolution in
patients with herpes zoster: a meta-analysis of placebo-controlled trials. Clin Infect Dis 1996; 22(2): 341-7.
77.
Jackson JL, Gibbons R, Meyer G, Inouye L. The effect of treating herpes zoster with oral acyclovir in preventing
postherpetic neuralgia. A meta-analysis. Arch Intern Med 1997; 157(8): 909-12.
78.
Crooks RJ, Jones DA, Fiddian AP. Zoster-associated chronic pain: an overview of clinical trials with acyclovir.
Scand J Infect Dis Suppl 1991; 80: 62-8.
79.
Huff JC, Drucker JL, Clemmer A, et al. Effect of oral acyclovir on pain resolution in herpes zoster: a reanalysis. J
Med Virol 1993; Suppl 1: 93-6.
80.
Morton P, Thomson AN. Oral acyclovir in the treatment of herpes zoster in general practice. N Z Med J 1989;
102(863): 93-5.
81.
Harding SP, Porter SM. Oral acyclovir in herpes zoster ophthalmicus. Curr Eye Res 1991; 10 Suppl: 177-82.
82.
Beutner KR, Friedman DJ, Forszpaniak C, Andersen PL, Wood MJ. Valaciclovir compared with acyclovir for
improved therapy for herpes zoster in immunocompetent adults. Antimicrob Agents Chemother 1995; 39(7): 154653.
83.
Degreef H. Famciclovir, a new oral antiherpes drug: results of the first controlled clinical study demonstrating its
efficacy and safety in the treatment of uncomplicated herpes zoster in immunocompetent patients. Int J Antimicrob
Agents 1994; 4(4): 241-6.
84.
Dworkin RH, Boon RJ, Griffin DR, Phung D. Postherpetic neuralgia: impact of famciclovir, age, rash severity, and
acute pain in herpes zoster patients. J Infect Dis 1998; 178 Suppl 1: S76-80.
85.
Tyring S, Barbarash RA, Nahlik JE, et al. Famciclovir for the treatment of acute herpes zoster: effects on acute
disease and postherpetic neuralgia. A randomized, double-blind, placebo-controlled trial. Collaborative Famciclovir
Herpes Zoster Study Group. Ann Intern Med 1995; 123(2): 89-96.
86.
Wassilew SW, Wutzler P. Oral brivudin in comparison with acyclovir for herpes zoster: a survey study on
postherpetic neuralgia. Antiviral Res 2003; 59(1): 57-60.
87.
Baena-Cañada JM, Martínez MJ, García-Olmedo O, Jiménez-Bárcenas R, Muriel-Cueto P. Interaction between
capecitabine and brivudin in a patient with breast cancer. Nat Rev Clin Oncol 2010; 7(1): 55-8.
88.
Rätz Bravo AE, Hofer S, Krähenbühl S, Ludwig C. Fatal drug-drug interaction of brivudine and capecitabine. Acta
Oncol 2009; 48(4): 631-3.
89.
Chono K, Katsumata K, Kontani T, et al. ASP2151, a novel helicase-primase inhibitor, possesses antiviral activity
against varicella-zoster virus and herpes simplex virus types 1 and 2. J Antimicrob Chemother 2010; 65(8): 1733-41.
90.
Kawashima M, Nemoto O, Honda M, et al. Amenamevir, a novel helicase-primase inhibitor, for treatment of herpes
zoster: A randomized, double-blind, valaciclovir-controlled phase 3 study. J Dermatol 2017; 44(11): 1219-27.
91.
Whitley RJ, Weiss H, Gnann JW, Jr., et al. Acyclovir with and without prednisone for the treatment of herpes zoster.
A randomized, placebo-controlled trial. The National Institute of Allergy and Infectious Diseases Collaborative
Antiviral Study Group. Ann Intern Med 1996; 125(5): 376-83.
92.
Wood MJ, Johnson RW, McKendrick MW, Taylor J, Mandal BK, Crooks J. A randomized trial of acyclovir for 7
70
Asano Y, Shiraki K, Takahashi M, Nagai H, Ozaki T, Yazaki T. Soluble skin test antigen of varicella-zoster virus
prepared from the fluid of infected cultures. J Infect Dis 1981; 143(5): 684-92.
76.
Wood MJ, Kay R, Dworkin RH, Soong SJ, Whitley RJ. Oral acyclovir therapy accelerates pain resolution in
patients with herpes zoster: a meta-analysis of placebo-controlled trials. Clin Infect Dis 1996; 22(2): 341-7.
77.
Jackson JL, Gibbons R, Meyer G, Inouye L. The effect of treating herpes zoster with oral acyclovir in preventing
postherpetic neuralgia. A meta-analysis. Arch Intern Med 1997; 157(8): 909-12.
78.
Crooks RJ, Jones DA, Fiddian AP. Zoster-associated chronic pain: an overview of clinical trials with acyclovir.
Scand J Infect Dis Suppl 1991; 80: 62-8.
79.
Huff JC, Drucker JL, Clemmer A, et al. Effect of oral acyclovir on pain resolution in herpes zoster: a reanalysis. J
Med Virol 1993; Suppl 1: 93-6.
80.
Morton P, Thomson AN. Oral acyclovir in the treatment of herpes zoster in general practice. N Z Med J 1989;
102(863): 93-5.
81.
Harding SP, Porter SM. Oral acyclovir in herpes zoster ophthalmicus. Curr Eye Res 1991; 10 Suppl: 177-82.
82.
Beutner KR, Friedman DJ, Forszpaniak C, Andersen PL, Wood MJ. Valaciclovir compared with acyclovir for
improved therapy for herpes zoster in immunocompetent adults. Antimicrob Agents Chemother 1995; 39(7): 154653.
83.
Degreef H. Famciclovir, a new oral antiherpes drug: results of the first controlled clinical study demonstrating its
efficacy and safety in the treatment of uncomplicated herpes zoster in immunocompetent patients. Int J Antimicrob
Agents 1994; 4(4): 241-6.
84.
Dworkin RH, Boon RJ, Griffin DR, Phung D. Postherpetic neuralgia: impact of famciclovir, age, rash severity, and
acute pain in herpes zoster patients. J Infect Dis 1998; 178 Suppl 1: S76-80.
85.
Tyring S, Barbarash RA, Nahlik JE, et al. Famciclovir for the treatment of acute herpes zoster: effects on acute
disease and postherpetic neuralgia. A randomized, double-blind, placebo-controlled trial. Collaborative Famciclovir
Herpes Zoster Study Group. Ann Intern Med 1995; 123(2): 89-96.
86.
Wassilew SW, Wutzler P. Oral brivudin in comparison with acyclovir for herpes zoster: a survey study on
postherpetic neuralgia. Antiviral Res 2003; 59(1): 57-60.
87.
Baena-Cañada JM, Martínez MJ, García-Olmedo O, Jiménez-Bárcenas R, Muriel-Cueto P. Interaction between
capecitabine and brivudin in a patient with breast cancer. Nat Rev Clin Oncol 2010; 7(1): 55-8.
88.
Rätz Bravo AE, Hofer S, Krähenbühl S, Ludwig C. Fatal drug-drug interaction of brivudine and capecitabine. Acta
Oncol 2009; 48(4): 631-3.
89.
Chono K, Katsumata K, Kontani T, et al. ASP2151, a novel helicase-primase inhibitor, possesses antiviral activity
against varicella-zoster virus and herpes simplex virus types 1 and 2. J Antimicrob Chemother 2010; 65(8): 1733-41.
90.
Kawashima M, Nemoto O, Honda M, et al. Amenamevir, a novel helicase-primase inhibitor, for treatment of herpes
zoster: A randomized, double-blind, valaciclovir-controlled phase 3 study. J Dermatol 2017; 44(11): 1219-27.
91.
Whitley RJ, Weiss H, Gnann JW, Jr., et al. Acyclovir with and without prednisone for the treatment of herpes zoster.
A randomized, placebo-controlled trial. The National Institute of Allergy and Infectious Diseases Collaborative
Antiviral Study Group. Ann Intern Med 1996; 125(5): 376-83.
92.
Wood MJ, Johnson RW, McKendrick MW, Taylor J, Mandal BK, Crooks J. A randomized trial of acyclovir for 7
70